Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat

Quanterix has a new chief executive and president in Everett Cunningham, but analysts at Leerink see Illumina’s former commercial chief facing an uphill battle in his bid to turn the medtech’s fortunes around.

Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute, Eric Green, M.D., Ph.D., will now step into the commercial life sciences world as the new chief medical officer of Illumina.

Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year.

Parabiosis Medicines raises $305 million to upend the status quo Biotech startup Parabiosis Medicines has raised $305 million in a Series A financing round led by ARCH Venture Partners, with participation from Perceptive Advisors and…

Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.

Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.

Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.